Evidence-Based Biosafety: a Review of the Principles and Effectiveness of Microbiological Containment Measures

SUMMARY We examined the available evidence on the effectiveness of measures aimed at protecting humans and the environment against the risks of working with genetically modified microorganisms (GMOs) and with non-GMO pathogenic microorganisms. A few principles and methods underlie the current biosafety practice: risk assessment, biological containment, concentration and enclosure, exposure minimization, physical containment, and hazard minimization. Many of the current practices are based on experience and expert judgment. The effectiveness of biosafety measures may be evaluated at the level of single containment equipment items and procedures, at the level of the laboratory as a whole, or at the clinical-epidemiological level. Data on the containment effectiveness of equipment and laboratories are scarce and fragmented. Laboratory-acquired infections (LAIs) are therefore important for evaluating the effectiveness of biosafety. For the majority of LAIs there appears to be no direct cause, suggesting that failures of biosafety were not noticed or that containment may have been insufficient. The number of reported laboratory accidents associated with GMOs is substantially lower than that of those associated with non-GMOs. It is unknown to what extent specific measures contribute to the overall level of biosafety. We therefore recommend that the evidence base of biosafety practice be strengthened.

[1]  Z. Memish,et al.  Brucellosis in laboratory workers at a Saudi Arabian hospital. , 2001, American journal of infection control.

[2]  Peter Neubauer,et al.  An expression vector system providing plasmid stability and conditional suicide of plasmid-containing cells , 1992, Applied Microbiology and Biotechnology.

[3]  D. Duan,et al.  Adeno-associated virus vectors , 1992 .

[4]  T. Komori,et al.  [Current biosafety in clinical laboratories in Japan: report of questionnaires' data obtained from clinical laboratory personnel in Japan]. , 2007, Kansenshogaku zasshi. The Journal of the Japanese Association for Infectious Diseases.

[5]  M. Kortepeter,et al.  Risk of occupationally acquired illnesses from biological threat agents in unvaccinated laboratory workers. , 2004, Biosecurity and bioterrorism : biodefense strategy, practice, and science.

[6]  I. Salkin Laboratory-Acquired Meningococcal Disease—United States, 2000 , 2002 .

[7]  P. Andersen,et al.  The success and failure of BCG — implications for a novel tuberculosis vaccine , 2005, Nature Reviews Microbiology.

[8]  D. Normile Infectious diseases. Second lab accident fuels fears about SARS. , 2004, Science.

[9]  N. Moussatché,et al.  Accidental Infection of Laboratory Worker with Vaccinia , 2003, Emerging Infectious Diseases.

[10]  J. Waner,et al.  Laboratory-acquired vaccinia infection. , 2004, Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology.

[11]  S. Isaacs Working Safely with Vaccinia Virus , 2004 .

[12]  Tiina Reponen,et al.  Do N95 respirators provide 95% protection level against airborne viruses, and how adequate are surgical masks? , 2006, American journal of infection control.

[13]  J. Hansen,et al.  Safe sorting of GFP-transduced live cells for subsequent culture using a modified FACS vantage. , 1999, Cytometry.

[14]  F. Meinhardt,et al.  Strain development in Bacillus licheniformis: construction of biologically contained mutants deficient in sporulation and DNA repair. , 2005, Journal of biotechnology.

[15]  D. Hunt,et al.  Biological safety : principles and practices , 2006 .

[16]  D. Fleming,et al.  Laboratory-acquired meningococcal disease--United States, 2000. , 2002, MMWR. Morbidity and mortality weekly report.

[17]  G. B. Phillips,et al.  Laboratory design for microbiological safety. , 1967, Applied microbiology.

[18]  Titenko Am [Marburg hemorrhagic fever]. , 1991, Zhurnal mikrobiologii, epidemiologii, i immunobiologii.

[19]  F. Siñeriz,et al.  The Argentine Experience in Enhancing Biosafety through Good Laboratory Practices , 2006 .

[20]  Pablo Yagupsky, Nechama Peled, Klaris Riesenberg, Exposure of Hospital Personnel to Brucella melitensis and Occurrence of Laboratory-acquired Disease in an Endemic Area , 2000 .

[21]  C. D. Miller,et al.  A twenty-five year review of laboratory-acquired human infections at the National Animal Disease Center. , 1987, American Industrial Hygiene Association journal.

[22]  S. Blower,et al.  Theory versus Data: How to Calculate R0? , 2007, PloS one.

[23]  A. Seidler,et al.  Review of Epidemiological Studies on the Occupational Risk of Tuberculosis in Low-Incidence Areas , 2005, Respiration.

[24]  L R Murphy,et al.  Compliance with universal precautions among health care workers at three regional hospitals. , 1996, American journal of infection control.

[25]  M. Singer,et al.  Asilomar conference on recombinant DNA molecules. , 1975, Science.

[26]  R. Salmon,et al.  Vero cytotoxin‐producing Escherichia coli O157 in beefburgers linked to an outbreak of diarrhoea, haemorrhagic colitis and haemolytic uraemic syndrome in Britain , 1994, Letters in applied microbiology.

[27]  E. Bernasconi,et al.  Brucellosis: An occupational hazard for medical laboratory personnel. Report of five cases , 2005, Infection.

[28]  K. Killeen,et al.  Safety and immunogenicity of phoP/phoQ-deleted Salmonella typhi expressing Helicobacter pylori urease in adult volunteers. , 1999, Vaccine.

[29]  L. Steidler,et al.  Live genetically modified bacteria as drug delivery tools: at the doorstep of a new pharmacology? , 2004, Expert opinion on biological therapy.

[30]  Caroline C. Johnson,et al.  Ocular Vaccinia Infection in Laboratory Worker, Philadelphia, 2004 , 2006, Emerging infectious diseases.

[31]  D. O'reilly,et al.  Baculovirus expression vectors: a laboratory manual. , 1992 .

[32]  R Osborne,et al.  Performance of open‐fronted microbiological safety cabinets: the value of operator protection tests during routine servicing , 1999, Journal of applied microbiology.

[33]  B. Wallace,et al.  Laboratory-acquired Brucellosis , 2004, Emerging infectious diseases.

[34]  E. Paoletti Applications of pox virus vectors to vaccination: an update. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[35]  M. S. Barbeito,et al.  Containment of microbial aerosols in a microbiological safety cabinet. , 1968, Applied microbiology.

[36]  D Walker,et al.  A survey of infections in United Kingdom laboratories, 1994-1995. , 1999, Journal of clinical pathology.

[37]  R. Hanson,et al.  Arbovirus infections of laboratory workers. Extent of problem emphasizes the need for more effective measures to reduce hazards. , 1967, Science.

[38]  J. Ring,et al.  Laboratory acquired infection with recombinant vaccinia virus containing an immunomodulating construct. , 2003, The Journal of investigative dermatology.

[39]  Laura H. Kahn Biodefense research: can secrecy and safety coexist? , 2004, Biosecurity and bioterrorism : biodefense strategy, practice, and science.

[40]  Smallpox and Its Eradication , 1988 .

[41]  W. Lim,et al.  Laboratory containment of SARS virus. , 2006, Annals of the Academy of Medicine, Singapore.

[42]  A. G. Wedum II. AIRBORNE INFECTION IN THE LABORATORY. , 1964, American journal of public health and the nation's health.

[43]  S. Gorbach Recombinant DNA: an infectious disease perspective. , 1978, The Journal of infectious diseases.

[44]  A. G. Wedum Control of laboratory airborne infection. , 1961, Bacteriological reviews.

[45]  H. Feldmann,et al.  Emerging and reemerging of filoviruses. , 1996, Archives of virology. Supplementum.

[46]  Arturo Casadevall,et al.  Host-Pathogen Interactions: Redefining the Basic Concepts of Virulence and Pathogenicity , 1999, Infection and Immunity.

[47]  Hao Wang,et al.  Biosafety Level 3 Laboratory for Autopsies of Patients with Severe Acute Respiratory Syndrome: Principles, Practices, and Prospects , 2005, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[48]  Marburg hemorrhagic fever , 2020, Definitions.

[49]  D. Normile SARS Experts Want Labs to Improve Safety Practices , 2003, Science.

[50]  J. Trempe,et al.  A helper virus-free packaging system for recombinant adeno-associated virus vectors. , 1999, Gene.

[51]  N. Grist,et al.  Infections in British clinical laboratories, 1988-1989. , 1991, Journal of clinical pathology.

[52]  Kennedy Da,et al.  Microbiological safety cabinets: selection, installation, testing and use. , 2000 .

[53]  Heinz Feldmann,et al.  Ebola virus: from discovery to vaccine , 2003, Nature Reviews Immunology.

[54]  S. Knudsen,et al.  Development and testing of improved suicide functions for biological containment of bacteria , 1995, Applied and environmental microbiology.

[55]  H. Bourne,et al.  Lassa fever, a new virus disease of man from West Africa. II. Report of a laboratory-acquired infection treated with plasma from a person recently recovered from the disease. , 1970, The American journal of tropical medicine and hygiene.

[56]  K L Keatley Controversy over genetically modified organisms: the governing laws and regulations. , 2000, Quality assurance.

[57]  R. Koup,et al.  Viable infectious cell sorting in a BSL-3 facility. , 2004, Methods in molecular biology.

[58]  Nikiforov Vv,et al.  A case of a laboratory infection with Marburg fever , 1994 .

[59]  W. Emmett Barkley,et al.  Biosafety in microbiological and biomedical laboratories , 1984 .

[60]  M. Poznansky,et al.  The development of a gene therapy , 1997, International journal of STD & AIDS.

[61]  R. Rico-Hesse,et al.  New arenavirus isolated in Brazil , 1994, The Lancet.

[62]  R. Good,et al.  Biosafety in the clinical mycobacteriology laboratory. , 1996, Clinics in laboratory medicine.

[63]  H. Smith Is it safe to use Escherichia coli K12 in recombinant DNA experiments? , 1978, The Journal of infectious diseases.

[64]  Samuel I. Miller,et al.  Lipid A mutant Salmonella with suppressed virulence and TNFα induction retain tumor-targeting in vivo , 1999, Nature Biotechnology.

[65]  D. Simpson,et al.  Fatal human disease from vervet monkeys. , 1967, Lancet.

[66]  J. Lanser,et al.  A Comparative Study of Methods To Validate Formaldehyde Decontamination of Biological Safety Cabinets , 1999, Applied and Environmental Microbiology.

[67]  David E. Swayne,et al.  Characterization of the Reconstructed 1918 Spanish Influenza Pandemic Virus , 2005, Science.

[68]  J. Sejvar,et al.  Assessing the Risk of Laboratory-Acquired Meningococcal Disease , 2005, Journal of Clinical Microbiology.

[69]  D. Ashford,et al.  Descriptive profile of tuberculin skin testing programs and laboratory-acquired tuberculosis infections in public health laboratories , 1997, Journal of clinical microbiology.

[70]  Christopher Dye,et al.  The growing burden of tuberculosis: global trends and interactions with the HIV epidemic. , 2003, Archives of internal medicine.

[71]  Ingrid Schmid,et al.  Biosafety concerns for shared flow cytometry core facilities , 2003, Cytometry. Part A : the journal of the International Society for Analytical Cytology.

[72]  K. Killeen,et al.  Advances in the development of bacterial vector technology , 2003, Expert review of vaccines.

[73]  Jonathan Y. Richmond,et al.  Biosafety in microbiological and biomedical laboratories , 1999 .

[74]  G. Lloyd,et al.  A case of Ebola virus infection. , 1977, British medical journal.

[75]  Diane O. Fleming,et al.  Epidemiology of laboratory-associated infections. , 2006 .

[76]  L. Bermudez,et al.  In vivo efficacy of phage therapy for Mycobacterium avium infection as delivered by a nonvirulent mycobacterium. , 2006, Microbial drug resistance.

[77]  S. Cryz,et al.  Phase I clinical trials of aroA aroD and aroA aroD htrA attenuated S. typhi vaccines; effect of formulation on safety and immunogenicity. , 2000, Vaccine.

[78]  A. G. Wedum Bacteriological safety. , 1953, American journal of public health and the nation's health.

[79]  A. G. Wedum LABORATORY SAFETY IN RESEARCH WITH INFECTIOUS AEROSOLS. , 1964, Public health reports.

[80]  G. Dougan,et al.  Salmonella typhi and S typhimurium derivatives harbouring deletions in aromatic biosynthesis and Salmonella Pathogenicity Island-2 (SPI-2) genes as vaccines and vectors. , 2003, Vaccine.

[81]  L. Naldini,et al.  Interaction of Human Immunodeficiency Virus-Derived Vectors with Wild-Type Virus in Transduced Cells , 1999, Journal of Virology.

[82]  E. Bouza,et al.  Laboratory-acquired brucellosis: a Spanish national survey. , 2005, The Journal of hospital infection.

[83]  D L Sewell,et al.  Laboratory-associated infections and biosafety , 1995, Clinical microbiology reviews.

[84]  V. V. Nikiforov,et al.  [A case of a laboratory infection with Marburg fever]. , 1994, Zhurnal mikrobiologii, epidemiologii, i immunobiologii.

[85]  A. Ramsay,et al.  Expression of Mouse Interleukin-4 by a Recombinant Ectromelia Virus Suppresses Cytolytic Lymphocyte Responses and Overcomes Genetic Resistance to Mousepox , 2001, Journal of Virology.

[86]  H. Pandha,et al.  Novel strains of Salmonella typhimurium as potential vectors for gene delivery. , 2004, FEMS microbiology letters.

[87]  S. Bavari,et al.  Reemergence of monkeypox: prevalence, diagnostics, and countermeasures. , 2005, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[88]  Dawn P. Wooley,et al.  Risk assessment of biological hazards. , 2006 .

[89]  V. Kiermer,et al.  Development of a sensitive assay for detection of replication-competent recombinant lentivirus in large-scale HIV-based vector preparations. , 2003, Molecular therapy : the journal of the American Society of Gene Therapy.

[90]  M. S. Barbeito,et al.  Microbiological hazard from the exhaust of a high-vacuum sterilizer , 1976, Applied and environmental microbiology.

[91]  J. Gonzalez,et al.  Brief report: treatment of a laboratory-acquired Sabiá virus infection. , 1995, The New England journal of medicine.

[92]  Karen K Mortland,et al.  Biosafety considerations in laboratory design. , 2003, Clinical leadership & management review : the journal of CLMA.

[93]  J. Riou,et al.  Enzyme electrophoresis, sero- and subtyping, and outer membrane protein characterization of two Neisseria meningitidis strains involved in laboratory-acquired infections , 1994, Journal of clinical microbiology.

[94]  G. B. Phillips,et al.  Laboratory design for study of infectious disease. , 1956, American journal of public health and the nation's health.

[95]  M. Levine,et al.  Safety and immunogenicity in humans of an attenuated Salmonella typhi vaccine vector strain expressing plasmid-encoded hepatitis B antigens stabilized by the Asd-balanced lethal vector system , 1997, Infection and immunity.

[96]  A. Giordano,et al.  Gene Transfer Technology in Therapy: Current Applications and Future Goals , 1999, The oncologist.

[97]  Second Lab Accident Fuels Fears About SARS , 2004, Science.

[98]  D. A. Dotson,et al.  Vaccinia (smallpox) vaccine: recommendations of the Advisory Committee on Immunization Practices (ACIP), 2001. , 2001, MMWR. Recommendations and reports : Morbidity and mortality weekly report. Recommendations and reports.

[99]  S. Zansky,et al.  Four Laboratory-Associated Cases of Infection with Escherichia coli O157:H7 , 2005, Journal of Clinical Microbiology.

[100]  B. Moss Genetically engineered poxviruses for recombinant gene expression, vaccination, and safety. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[101]  G. B. Phillips Microbiological hazards in the laboratory—Part one—Control , 1965 .

[102]  D. Scherman,et al.  A new DNA vehicle for nonviral gene delivery: supercoiled minicircle , 1997, Gene Therapy.

[103]  J. Piškur,et al.  Bacterial Toxin-Antitoxin Gene System as Containment Control in Yeast Cells , 2000, Applied and Environmental Microbiology.

[104]  J. Kaiser Accidents Spur a Closer Look at Risks at Biodefense Labs , 2007, Science.

[105]  R. Curtiss,et al.  Biological containment and cloning vector transmissibility. , 1978, The Journal of infectious diseases.

[106]  O. Käppeli,et al.  The science and intricacy of environmental safety evaluations. , 1997, Trends in biotechnology.

[107]  Mario Roederer,et al.  Measuring containment of viable infectious cell sorting in high‐velocity cell sorters , 2003, Cytometry. Part A : the journal of the International Society for Analytical Cytology.

[108]  I Schmid,et al.  Biosafety considerations for flow cytometric analysis of human immunodeficiency virus-infected samples. , 1999, Cytometry.

[109]  J. Modlin,et al.  Vaccinia (Smallpox) Vaccine Recommendations of the Advisory Committee on Immunization Practices (ACIP), 2001 , 2001 .

[110]  L. Hovelius,et al.  Report of Five Cases , 1977 .

[111]  R. Samulski Adeno-associated Viral Vectors , 1995 .

[112]  E. Gandsman,et al.  Sabia virus incident at Yale University. , 1997, American Industrial Hygiene Association journal.

[113]  G. Kochs,et al.  Replication fitness determines high virulence of influenza A virus in mice carrying functional Mx1 resistance gene , 2007, Proceedings of the National Academy of Sciences.

[114]  Erik Remaut,et al.  A phase I trial with transgenic bacteria expressing interleukin-10 in Crohn's disease. , 2006, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

[115]  R. Pike Past and present hazards of working with infectious agents. , 1978, Archives of pathology & laboratory medicine.

[116]  Raymond P. Clark Standards for safety cabinets , 1997, Nature.

[117]  H. Bouwer,et al.  Pathogenicity and Immunogenicity of aListeria monocytogenes Strain That Requiresd-Alanine for Growth , 1998, Infection and Immunity.

[118]  Jeff F. Miller,et al.  Safety and Shedding of an Attenuated Strain of Listeria monocytogenes with a Deletion of actA/plcB in Adult Volunteers: a Dose Escalation Study of Oral Inoculation , 2002, Infection and Immunity.

[119]  R. Kruse Potential aerogenic laboratory hazards of Cocidioides immitis. , 1962, American journal of clinical pathology.

[120]  E. V. Sargent,et al.  Use of personal protective equipment for respiratory protection. , 2003, ILAR journal.

[121]  C. H. Nelson,et al.  Risk Perception, Behavior, and Consumer Response to Genetically Modified Organisms , 2001 .

[122]  J. Glorioso,et al.  8 Gene-transfer Tool: Herpes Simplex Virus Vectors , 1999 .

[123]  Thomas A. Kost,et al.  Biosafety and Viral Gene Transfer Vectors , 2006 .

[124]  Z. Debyser Biosafety of lentiviral vectors. , 2003, Current gene therapy.

[125]  W. Goebel,et al.  Delivery of antigen-encoding plasmid DNA into the cytosol of macrophages by attenuated suicide Listeria monocytogenes , 1998, Nature Biotechnology.

[126]  B. Herwaldt Laboratory-Acquired Parasitic Infections from Accidental Exposures , 2001, Clinical Microbiology Reviews.

[127]  J. Frame,et al.  Lassa fever, a new virus disease of man from West Africa. I. Clinical description and pathological findings. , 1970, The American journal of tropical medicine and hygiene.

[128]  N. Andrews,et al.  Risk of laboratory-acquired meningococcal disease. , 2001, The Journal of hospital infection.

[129]  R. Pike,et al.  Laboratory-associated infections: incidence, fatalities, causes, and prevention. , 1979, Annual review of microbiology.

[130]  R. Pike,et al.  Survey of laboratory-acquired infections. , 1951, American journal of public health and the nation's health.

[131]  Ingrid Schmid,et al.  International Society for Analytical Cytology Biosafety Standard for Sorting of Unfixed Cells , 2007, Cytometry. Part A : the journal of the International Society for Analytical Cytology.

[132]  Edward Elton,et al.  The Effect of Microbiological Containment Systems on Dexterity , 2007, Journal of occupational and environmental hygiene.

[133]  K. Riesenberg,et al.  Exposure of hospital personnel to Brucella melitensis and occurrence of laboratory-acquired disease in an endemic area. , 2000, Scandinavian journal of infectious diseases.

[134]  R. Pike,et al.  Laboratory-associated infections: summary and analysis of 3921 cases. , 1976, Health laboratory science.

[135]  N. de Wind,et al.  Mutagenesis and characterization of a 41-kilobase-pair region of the pseudorabies virus genome: transcription map, search for virulence genes, and comparison with homologs of herpes simplex virus type 1. , 1994, Virology.

[136]  A. Voss,et al.  Laboratory diagnosis and biosafety issues of biological warfare agents. , 2002, Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases.

[137]  Jean Paul Remon,et al.  Biological containment of genetically modified Lactococcus lactis for intestinal delivery of human interleukin 10 , 2003, Nature Biotechnology.

[138]  M. First,et al.  Effects of airflow rates and operator activity on containment of bacterial aerosols in a class II safety cabinet , 1984, Applied and environmental microbiology.

[139]  Mengji Lu,et al.  Improving the biosafety of cell sorting by adaptation of a cell sorting system to a biosafety cabinet , 2005, Cytometry. Part A : the journal of the International Society for Analytical Cytology.

[140]  B. Moss,et al.  Accidental human vaccination with vaccinia virus expressing nucleoprotein gene , 1986, Nature.

[141]  D. Henderson,et al.  Potential for laboratory exposures to biohazardous agents found in blood. , 1990, American journal of public health.

[142]  P. Openshaw,et al.  Accidental infection of laboratory worker with recombinant vaccinia virus , 1991, The Lancet.

[143]  T. Dull,et al.  Large‐scale manufacturing of safe and efficient retrovirus packaging lines for use in immunotherapy protocols , 1999 .

[144]  T. Kimman,et al.  Non-transmissible pseudorabies virus gp50 mutants: a new generation of safe live vaccines. , 1994, Vaccine.

[145]  Christopher W. Wong,et al.  Laboratory-acquired severe acute respiratory syndrome. , 2004, The New England journal of medicine.

[146]  J. Coia Nosocomial and laboratory-acquired infection with Escherichia coli O157. , 1998, The Journal of hospital infection.

[147]  Hidekazu Nishimura,et al.  Enhanced virulence of influenza A viruses with the haemagglutinin of the 1918 pandemic virus , 2004, Nature.

[148]  A. K. Hansen,et al.  Marburg and Ebola virus infections in laboratory non-human primates: a literature review. , 2000, Comparative medicine.